GPC-3 CAR T cells for recurrent GPC-3 positive glioblastoma
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether a special type of immune cell (called CAR T cells) can fight a brain tumor called glioblastoma that has come back. The cells are made to target a protein on the tumor cells, and the study will see if this treatment is safe and helpful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of brain tumor called glioblastoma that has come back and has the GPC-3 protein.
- You must be healthy enough to have surgery to remove the tumor again (the cells are given during or after this surgery).
- You must be able to care for yourself (Karnofsky score of 60% or more).
- Your organs (kidneys, liver, blood cells, and lungs) must be working well enough, and you must not have serious infections (unless it's hepatitis B or C).
- You must agree to use effective birth control for 3 months after the cell infusion if you are sexually active.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special type of immune cell treatment (CAR T cells) for a rare brain tumor called ATRT that has come back after standard treatment. The cells are made to find and attack tumor cells that carry a marker called GPC3, which may help reduce or control the tumor.
This trial tests a new type of immunotherapy called CAR T cells that are trained to find and attack cancer cells with a specific marker (GPC3). The CAR T cells are also 'armored' with extra proteins (IL-15 and IL-21) to help them work better. It might be an option for adults with advanced solid tumors, especially liver cancer, that have not responded to standard treatments.
This Phase 1 study tests a customized immune-cell treatment (CAR T cells) made to recognize GPC3, a marker found on some tumors. It’s designed for children and young people whose solid tumors have not been cured by standard treatment and who can safely receive this therapy.
This trial tests a custom immune-cell treatment (CAR-T) that targets a marker called GPC3 in people with advanced hepatocellular carcinoma (a type of liver cancer). It’s for cases where standard treatments have not worked well, and the goal is to shrink tumors and improve outcomes.
This study tests a new kind of immune therapy called CAR T-cells that are specially designed to find and attack cancer cells that carry a protein called GPC3. Researchers want to see if this treatment is safe and helpful for people with solid tumors that have not responded to standard therapies.
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called GARP on your tumor cells. It is for people whose high-grade glioma (a fast-growing brain tumor) has come back after previous treatment.
Hear when a new Glioblastoma Multiforme of Brain trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.